Press Releases

Press Releases

Date Title and Summary Additional Formats
Jan 04, 2019 Catalyst Pharmaceuticals Announces Publication of Clinical Data from the Investigator-Sponsored Phase IIb Study Evaluating FirdapseĀ® for the Treatment of MuSK Antibody Positive Myasthenia Gravis
Published online in SAGE Open Medicine on December 17, 2018 CORAL GABLES, Fla. , Jan. 04, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating,